search
Back to results

Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants

Primary Purpose

BPD - Bronchopulmonary Dysplasia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NAVA technology to synchronize NIPPV
Sponsored by
New York Medical College
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for BPD - Bronchopulmonary Dysplasia

Eligibility Criteria

24 Weeks - 30 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Babies born less than 1kg.
  2. Babies born at 24-30 weeks gestation.
  3. Babies who qualify for surfactant administration within 90mins of birth:

    • FiO2 > 0.4,
    • nCPAP > 6, with
    • Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions.

Exclusion Criteria:

  1. Babies with Grade 3-4 IVH (may not be known prior to randomization).
  2. Babies with congenital anomalies including neuromuscular disorder.
  3. Babies who do not require intubation until 7 days of life.

Sites / Locations

  • Westchester Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

NIPPV

NAVA-NIPPV

Arm Description

non synchronized non invasive positive pressure ventilation

synchronized non invasive positive pressure ventilation with NAVA

Outcomes

Primary Outcome Measures

The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life
Mechanical ventilation via Endotracheal tube
The need for Mechanical Ventilation via ET tube ( MVET) at 28 days of life
Mechanical Ventilation via Endotracheal tube

Secondary Outcome Measures

Incidence of BPD or need for supplemental O2 at 36 weeks corrected age
Bronchopulmonary Dysplasia

Full Information

First Posted
July 30, 2018
Last Updated
March 24, 2023
Sponsor
New York Medical College
search

1. Study Identification

Unique Protocol Identification Number
NCT03613987
Brief Title
Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
Official Title
Randomized Control Trial: Synchronized Non-Invasive Positive Pressure Ventilation (sNIPPV) With Neurally-Assisted Ventilatory Assist (NAVA) Versus NIPPV in Extremely Low Birth Weight Infants
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
April 26, 2018 (Actual)
Primary Completion Date
July 26, 2022 (Actual)
Study Completion Date
July 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
New York Medical College

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Infants delivered weighing less than 1 kg at birth (ELBW) are at high risk for the development of bronchopulmonary dysplasia (BPD) and Ventilator-Induced Lung Injury (VILI), in part because of the need for mechanical ventilation utilizing an endotracheal tube (MVET). In spite of strategies to minimize the need for MVET, the incidence of BPD in ELBW infants continues to be 20-80%. The hypothesis is that synchronized NIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Detailed Description
Hypothesis: The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV. Specific Aims: The specific aims are to determine whether: sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV. sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent. Randomization: ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme. Extubation criteria: Infant is receiving caffeine. Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria: mean airway pressure (MAP) < 8cmH20, FiO2 < 0.4, pH > 7.2, and pCO2 < 70. Intubation criteria: Infants must be intubated if any of the following criteria occur: One apneic event requiring positive pressure ventilation (PPV). More than 6 apneic events requiring stimulation within a 6-hour period. A deterioration in respiratory status as noted by any of the following criteria: pH < 7.2, pCO2 > 70, FiO2 > 0.6, Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy. Data Collection: Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate. Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines). During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations. Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET. MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P < 0.05. Power analysis: Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group. Anticipated timeline: With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year. The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD. There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
BPD - Bronchopulmonary Dysplasia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NIPPV
Arm Type
No Intervention
Arm Description
non synchronized non invasive positive pressure ventilation
Arm Title
NAVA-NIPPV
Arm Type
Experimental
Arm Description
synchronized non invasive positive pressure ventilation with NAVA
Intervention Type
Device
Intervention Name(s)
NAVA technology to synchronize NIPPV
Intervention Description
Neurally adjust ventilator assist is used to synchronize the NIPPV
Primary Outcome Measure Information:
Title
The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life
Description
Mechanical ventilation via Endotracheal tube
Time Frame
7 days of life
Title
The need for Mechanical Ventilation via ET tube ( MVET) at 28 days of life
Description
Mechanical Ventilation via Endotracheal tube
Time Frame
28 days of life
Secondary Outcome Measure Information:
Title
Incidence of BPD or need for supplemental O2 at 36 weeks corrected age
Description
Bronchopulmonary Dysplasia
Time Frame
36 weeks corrected gestational age

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
30 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Babies born less than 1kg. Babies born at 24-30 weeks gestation. Babies who qualify for surfactant administration within 90mins of birth: FiO2 > 0.4, nCPAP > 6, with Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions. Exclusion Criteria: Babies with Grade 3-4 IVH (may not be known prior to randomization). Babies with congenital anomalies including neuromuscular disorder. Babies who do not require intubation until 7 days of life.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lance Parton, MD
Organizational Affiliation
Westchester Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Westchester Medical Center
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants

We'll reach out to this number within 24 hrs